Has Tara Harmonosky received payments from drug or device companies?

Yes. Drug and device makers reported $5,068 in general payments to Tara Harmonosky across 283 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tara Harmonosky did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tara Harmonosky come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tara Harmonosky

Family · Hazleton, PANPI 1588086763

Payments from drug & device makers

$5,068in general payments, 2019–2025

Across 283 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Vifor Pharma, Inc.$2K
Bayer$684
Amgen$319
AstraZeneca$313
GSK$265
Daiichi Sankyo Inc.$237
plus $2K from 20 others

What the payments were for

Food & beverage$4,96498%
Education$1042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Vifor Pharma, Inc.	95	$1,699
Bayer	48	$684
Amgen	14	$319
AstraZeneca(2 entities)	16	$313
GSK	19	$265
Daiichi Sankyo Inc.	17	$237
Calliditas Therapeutics US Inc.	7	$156
Boehringer Ingelheim	7	$156
Akebia Therapeutics Inc	8	$156
Nxstage Medical, Inc.	2	$120
Travere Therapeutics, Inc.	6	$118
Mallinckrodt Hospital Products Inc.	5	$105
OPKO Pharmaceuticals, LLC	6	$101
Fresenius USA Marketing, Inc.	5	$100
Otsuka America Pharmaceutical, Inc.	5	$85
Lilly USA, LLC	3	$64
Kyowa Kirin, Inc.	3	$62
Ardelyx, Inc.	3	$54
Otsuka Pharmaceutical Development & Commercialization, Inc.	3	$52
Bard Peripheral Vascular, Inc.	2	$40
Novartis	2	$38
Aurinia Pharma U.S., Inc.	2	$36
Ultragenyx Pharmaceutical Inc.	2	$35
Medtronic	1	$32
Takeda Pharmaceuticals U.S.A., Inc.	1	$25
Pfizer	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Veltassa$122

How this compares

$5,068 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VelphoroSucroferric Oxyhydroxide	14	$84,446
VeltassaPatiromer Calcium Sorbitex	35	$53,264
Sevelamer Carbonate	35	$12,214
Calcitriol	294	$5,637
Calcium Acetate	33	$4,229
Doxazosin Mesylate	66	$2,087
Midodrine Hcl	25	$1,699
Potassium Chloride	29	$1,347
Allopurinol	124	$1,092
Losartan Potassium	55	$1,069
Lisinopril	60	$849
Amlodipine Besylate	76	$787
Metoprolol Succinate	35	$716
Diltiazem 24hr Er (Cd)Diltiazem Hcl	14	$679
Hydralazine Hcl	42	$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro	$100	$84,44614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Hazleton

Kathleen ScholzPittsburgh$397K
Shannon FitzgeraldAllison Park$370K
Stephanie HarshbargerCamp Hill$317K
Whitney BowlesFort Washington$253K
Kweilynn GreenePittsburgh$139K
Jessica LindenbergerPittsburgh$131K
Kami NestlerWilkes Barre$129K
Bethany ThomasPhiladelphia$126K
Margaret RosenzweigPittsburgh$89K
Amanda GrippoDickson Cty$86K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →